Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 MillionGlobeNewsWire • 09/02/25
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 MillionGlobeNewsWire • 09/02/25
Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 millionReuters • 08/25/25
Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 MillionGlobeNewsWire • 08/25/25
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 MillionBusiness Wire • 08/25/25
Here's What Key Metrics Tell Us About Royalty Pharma (RPRX) Q2 EarningsZacks Investment Research • 08/06/25
Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • 08/05/25
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of DirectorsGlobeNewsWire • 07/17/25
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025GlobeNewsWire • 07/16/25
Royalty Pharma: Attractive Acquisition With Upside Risk/Reward On Current PipelineSeeking Alpha • 07/01/25
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 BillionGlobeNewsWire • 06/24/25
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewsWire • 06/04/25
Royalty Pharma Announces Shareholder Approval of its External Manager AcquisitionGlobeNewsWire • 05/12/25
Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to SayZacks Investment Research • 05/08/25
Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/08/25